scholarly journals Label-free in vivo imaging of myelinated axons in health and disease with spectral confocal reflectance microscopy

2014 ◽  
Vol 20 (4) ◽  
pp. 443-449 ◽  
Author(s):  
Aaron J Schain ◽  
Robert A Hill ◽  
Jaime Grutzendler
2003 ◽  
Vol 11 (24) ◽  
pp. 3171 ◽  
Author(s):  
Kung-Bin Sung ◽  
Rebecca Richards-Kortum ◽  
Michele Follen ◽  
Anais Malpica ◽  
Chen Liang ◽  
...  

2008 ◽  
Author(s):  
Chiao-Ying Lin ◽  
Vladimir Hovhannisyan ◽  
June-Tai Wu ◽  
Sung-Jan Lin ◽  
Chii-Wann Lin ◽  
...  

2017 ◽  
Vol 8 (1) ◽  
Author(s):  
Junhwan Kwon ◽  
Moonseok Kim ◽  
Hyejin Park ◽  
Bok-Man Kang ◽  
Yongjae Jo ◽  
...  

2014 ◽  
Vol 36 (2) ◽  
pp. E8 ◽  
Author(s):  
Joseph Georges ◽  
Aqib Zehri ◽  
Elizabeth Carlson ◽  
Joshua Nichols ◽  
Michael A. Mooney ◽  
...  

Glioblastoma is the most common primary brain tumor with a median 12- to 15-month patient survival. Improving patient survival involves better understanding the biological mechanisms of glioblastoma tumorigenesis and seeking targeted molecular therapies. Central to furthering these advances is the collection and storage of surgical biopsies (biobanking) for research. This paper addresses an imaging modality, confocal reflectance microscopy (CRM), for safely screening glioblastoma biopsy samples prior to biobanking to increase the quality of tissue provided for research and clinical trials. These data indicate that CRM can immediately identify cellularity of tissue biopsies from animal models of glioblastoma. When screening fresh human biopsy samples, CRM can differentiate a cellular glioblastoma biopsy from a necrotic biopsy without altering DNA, RNA, or protein expression of sampled tissue. These data illustrate CRM's potential for rapidly and safely screening clinical biopsy samples prior to biobanking, which demonstrates its potential as an effective screening technique that can improve the quality of tissue biobanked for patients with glioblastoma.


Sign in / Sign up

Export Citation Format

Share Document